Equities

Summit Therapeutics Inc

SMMT:NMQ

Summit Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.42
  • Today's Change-0.20 / -1.07%
  • Shares traded2.03m
  • 1 Year change+830.30%
  • Beta-0.9162
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Summit Therapeutics Inc have a median target of 32.00, with a high estimate of 44.00 and a low estimate of 5.00. The median estimate represents a 73.72% increase from the last price of 18.42.
High138.9%44.00
Med73.7%32.00
Low-72.9%5.00

Earnings history & estimates in USD

On Oct 30, 2024, Summit Therapeutics Inc reported 3rd quarter 2024 losses of -0.08 per share.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate-38.57%
Summit Therapeutics Inc reported annual 2021 losses of -4.80 per share on Mar 17, 2022.
Average growth rate+18.95%
More ▼

Revenue history & estimates in USD

Summit Therapeutics Inc had revenues for the full year 2021 of 1.81m. This was 91.34% below the prior year's results.
Average growth rate-6.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.